life sciences : Innovation + Job News

Academy of Natural Sciences and Drexel announce historic partnership

Flying Kite Media Tuesday, May 24, 2011

Sixteen tons of dinosaur bones. Let's start in a lab somewhere in the vast reaches of the Academy of Natural Sciences. Drexel University paleontology professor Kenneth Lacovara has been using the Academy's research facilities for over a decade.

The Academy of Natural Sciences and Drexel University have announced that they are joining forces. Pending approval of both boards, the Parkway stalwart will henceforth be known as The Academy of Natural Sciences of Drexel University.

Drexel will take over management of the Academy's $61 million endowment. It is an innovative strategy that could set a standard for institutional partnerships nationwide, says Gary Steuer, head of Arts, Culture and Creative Economy for the City of Philadelphia. Compared to its West Philadelphia neighbor Penn, Drexel has not had signature cultural facilities, adds Steuer.

In what Lacovara terms a win all around, leveraging scientific assets at both institutions, students and faculty at Drexel will have access to one of the greatest science collections, rated top-10 worldwide, and the museum will have access to Drexel's growing Media Arts and Design school to enhance exhibit design. Lacovara points to grad student Evan Boucher who digitally reconstructed and animated a 65 million year-old crocodile whose bones were discovered right across the Delaware in Sewell, N.J.

The Academy is "much more than a place for school trips," says Steuer, who views the Drexel/ANSP partnership as marrying a 19th century museum with forward thinking technological creativity.

Source: Ken Lacovara, PhD, Drexel University; Gary Steuer, City of Philadelphia
Writer: Sue Spolan

New Philly HQ for medical device firm Echo Therapeutics, hiring 25

Flying Kite Media Tuesday, May 17, 2011

Medical device company Echo Therapeutics has set up corporate headquarters in Philadelphia, and plans to hire 25 employees in the next year, according to CEO Patrick Mooney. The company is developing two devices, Prelude and Symphony, which offer a painless alternative to both blood glucose monitoring and drug delivery. The company has just announced the appointment of a CFO, creating a third member of the management team.

Life as a diabetic involves the sight of one's own blood, and a little bit of discomfort every time the needle pierces skin. Now imagine that part of the equation removed, replaced with a needle-free mechanism that can test blood sugar levels transdermally. Echo's Synmphony device gathers information transdermally and transmits it wirelessly.

"The tip looks like a little thimble, and there's a microprocessor inside the device that calculates the level of resistance. The thimble spins, removing dead skin. You don't feel anything, but it stops when it gets to live skin. Now you are literally on top of blood vessels and nerve endings, just microns away from live tissue," explains Mooney, a former surgeon who left medicine to work on Wall Street, and is now marrying his two career paths at the helm of the life sciences startup.

Echo's other device is a transdermal drug delivery system. The Prelude also takes advantage of that exact spot at the juncture of dead and live tissue to get drugs to the body without needles. Right now, the Prelude is being tested with lidocaine, a numbing agent, but the possibilities are vast.

The technology for the Prelude and Symphony was developed at MIT in Massachusetts by Dr. Bob Langer, and the manufacturing side of the business will remain in the Boston area. "I am from Philadelphia originally," says Pat Mooney of the corporate move to this area. "Philadelphia is in a great spot for biotech." Mooney calls the city a sweet spot for his pre-revenue company, citing the proximity of major pharmaceuticals, money managers in New York City, regulators in Washington, DC, and labs in Boston. Echo has just released its first quarter results, showing positive numbers across the board.

Source: Patrick Mooney, MD, Echo Therapeutics
Writer: Sue Spolan

Business leaders name area's top tech companies at PACT Enterprise Awards

Flying Kite Media Tuesday, May 10, 2011

It was like swimming in a sea of money. On May 4, The Greater Philadelphia Alliance for Capital and Technologies hosted the 18th Annual Enterprise Awards. About a thousand business leaders and executives attended. Beginning with a VIP reception, the kudos flowed as easily as the cocktails, while down the hall a larger food and drink fest filled with tuxedo and evening gown clad representatives from Philadelphia's top law and finance firms, who networked with the area's best and brightest entrepreneurs and incubators.

Out of 27 nominees, these are the results: the Life Sciences Startup Company award went to CareKinesis, Philly's top Technology Startup Company of 2011 is Monetate, an eCommerce leader that runs websites for Urban Outfitters and QVC; the area's Emerging Life Sciences Company was NuPathe, which works on branded therapeutics for diseases of the central nervous system; SevOne was named Emerging Technology Company, following a 2009 PACT award for Tech Startup, and this year's award for a MedTech Pioneering Company was sewn up by medical device provider Teleflex.

The award for MedTech Product Innovation went to Siemens Healthcare. The venerated Morgan Lewis attorney Stephen M. Goodman received the Legend Award for his many years assisting entrepreneurs; the IT Innovator Award of Excellence went to Lockheed Martin, Information Systems & Global Solutions � Defense, based in Maryland but with offices in King of Prussia. The Investment Deal of the Year went to Safeguard Scientifics for the acquisition of Clarient Inc., formerly in Safeguard's portfolio, purchased by GE Healthcare for $144 million. "It was a spectacular dinner," says attorney Michael Heller, one of the evening's presenters and Chair of Business Law at Cozen O'Connor. "It was wonderful to see such a terrific turnout among the venture capital community. The region is more active today than it was a year ago, and there's more excitement in the air regarding the VC community."

PACT judges named James Walker of Octagon Research Solutions Technology CEO of the Year; Life Sciences Company of the Year was Health Advocate, and ICG Commerce beat out HTH Worldwide and Qlik Tech to win Technology Company of the Year.

Prior to the event, three CleanTech Companies to Watch were named: ElectroPetroleum, NovaThermal Energy, and Viridity Energy. Video of the entire event is available here.

Source: Michael Heller, Cozen O'Connor; PACT Enterprise Awards
Writer: Sue Spolan

Photo : Attorney Stephen M. Goodman

Malvern biopharma startup Vicept on fast-track to get the red out

Flying Kite Media Tuesday, May 03, 2011

Rosacea is not a life threatening condition, but the facial redness of the disorder can be embarrassing enough to make a sufferer want to die. Rosacea is characterized by a red blush, spidery veins and acne-like pustules on the face. The condition may be intermittent or long term. Malvern-based Vicept is a specialty biopharmaceutical startup that has developed a topical cream that treats the most obvious symptom of the facial condition.

"There's nothing right now on the market that's strictly indicated for the treatment of the redness of rosacea," explains Vicept Director, President and CEO Neal Walker, MD. With $16 million in Investigational New Drug (IND) capital raised during a very tough time for the economy and for life sciences investment in particular, Vicept's prescription cream is an easy fix compared to other rosacea treatments on the market, none of which address the symptom of redness. Laser procedures are considered cosmetic and are not reimbursed by insurance; Oracea, a low dose antibiotic in pill form, affects the whole body and only targets the bumps and pimples, not the redness, according to Walker.

In contrast, Vicept's as-yet unnamed product goes after receptors in facial blood vessels, clamping them down with a vasoconstrictor mechanism and blanching out the redness. Walker is a practicing dermatologist and reports that the active ingredient in the cream has been around since the 1960s, and was originally in Afrin nasal spray.

Vicept has completed Phase 2 clinical studies and is ready to move on to Phase 3 as it continues to move the product along in development, talking with different types of potential partners for distribution both in North America and globally. The fast track company, founded in 2009, has seven full time employees and is nominated for a PACT Enterprise Award this year. Walker says he expects the prescription cream to be available within the next few years.

Source: Neal Walker, MD, Vicept
Writer: Sue Spolan

Viridity teams with Jefferson on smart grid, big battery

Flying Kite Media Tuesday, April 19, 2011

Thomas Jefferson University takes up a pretty big footprint in Center City, with a 13 acre campus just west of Washington Square. This week, Viridity Energy announced that it's partnering with Jefferson to provide an innovative energy storage program to optimize the University power grid.

On the heels of a smart grid project for SEPTA, Conshohocken-based Viridity approached Jefferson to gauge interest in a two-part program aimed at achieving optimal value from the school's wind power purchase. Audrey Zibelman, President and CEO of Viridity, notes that Jefferson is very forward looking in terms of how to manage energy, citing the university's recent acquisition of one-third of the electricity supply from Iberdrola Renewables' 102 megawatt Locust Ridge II wind power project located in Schuylkill County.

"Hospital demand is pretty flat. It doesn't peak. It's round the clock," explains Zibelman. But wind power is intermittent, and tends to be strongest at night. Sometimes the transmission system between the wind farm and the hospital is unavailable due to congestion. The environmentally-friendly solution is a giant battery to be installed on-site, which will store wind power when it's cheapest and most abundant, coupled with Viridity's dynamic load control optimization system. Viridity's proprietary VPower smart grid platform combines software with hardware to balance system loads, so that Jefferson can get the most cost efficient combination of wind power and traditional electric. When there is a surplus, VPower is set up to sell the energy back to the grid for a profit.

Zibelman says right now the project is in the planning stages. The company is in the market for a 1 to 1.5 megawatt battery, ranging in price from $750,000 to $3 million depending on vendor, chemistry, capacity and peripherals.

"The battery will not always be providing physical reliability," says Zibelman, "but it will always provide economic reliability. It's a revenue source that pays for itself." Jefferson's combination of Viridity's VPower technology coupled with the giant battery will create a micro energy community in the heart of Center City.

Source: Audrey Zibelman, Viridity Energy
Writer: Sue Spolan

CHOP Idol: Seacrest creates multimedia center at Children's Hospital

Flying Kite Media Tuesday, April 19, 2011

Ryan Seacrest! Is awesome! The media mogul has chosen Children's Hospital of Philadelphia to build The Voice, a state of the art multimedia studio. The Voice, a freestanding broadcast center funded by The Ryan Seacrest Foundation, is being built in the main lobby of CHOP, in the Colket Atrium. It will be accessible from the hospital's 34th street entrance and will serve CHOP patients and their visitors and families as a much-needed distraction.

Elana Brewer, CHOP's Director of Child Life, Education and Creative Arts Therapy, explains the setup: "Within the actual physical studio, there is a space designed for a DJ, as well as tabletop space for up to five patients, family members, siblings, celebrity visitors or guests to interact with the DJ."

Off mic, there will be additional seating for children who want to come to the studio but may be less inclined to jump on the mic. Two video cameras will capture the action in the studio, and the entire audio and video feed will be available throughout the internal TV system in the hospital buildings. Due to legal and privacy issues, Brewer says The Voice broadcasts will be strictly in-house, aimed exclusively at patients, families, friends and staff.

The Voice is designed so that passers by in the lobby can peer in through the curved glass partition, and its location in the atrium means that rooms and balconies overlooking the vast open space will have a direct line of sight into the broadcast center.

Brewer explains that tween, teen and young adult patients are the target audience for participation. It's a bit of a forgotten age, because younger children use playrooms, but there's not a lot to keep the older set happily occupied. "It's a great distraction," says Brewer. "The chance to use a state of the art studio will have a normalizing effect, and will give patients a sense of control often lost in the hospital environment." Brewer looks to The Voice as a creative outlet and a great opportunity for socialization, which is especially important for the adolescent population. Kids who are unable to leave their rooms will still be able to participate through on-air trivia quizzes and giveaways.
Seacrest selected CHOP as the second children's hospital in the country to be outfitted with The Voice. The flagship is at Children's Healthcare of Atlanta Pediatric Hospital. The Philadelphia location is scheduled to go live this summer.

Source: Elana Brewer, CHOP
Writer: Sue Spolan

Safeguard drops $25M on chip-enabled eyeglasses

Flying Kite Media Tuesday, April 12, 2011

Eyeglasses are about to change dramatically, thanks to a major investment by Safeguard Scientifics. The Wayne-based holding company, in an effort to expand its footprint in life sciences investments, announced that it has provided $25 million plus an additional $10 million in venture debt to PixelOptics, a medical technology company in Roanoke, Va., for its emPower! line of chip-enabled glasses aimed at bifocal and progressive lens wearers, of which there are a total of 100 million in the US alone. Safeguard's Senior Vice President and Managing Director in the Life Sciences Group, Gary Kurtzman MD, notes that investment in life sciences start ups is shrinking, and Safeguard is seeking new opportunities by getting into consumer-driven companies like PixelOptics.

Rather than divide eyeglasses so that the top section is corrective and the bottom section is for reading, emPower! glasses rely on a chip embedded in the frame which electronically transforms the focus of the entire lens from corrective to reading power at a touch. The chip is powered by a battery which lasts at least two years and requires recharging every three days.

Kurtzman says the new eyeglass technology has significant near term potential both as a product and for revenue, citing a low regulatory bar, a big market, and the fact that the product is ready to go to market. "We think it has all the features of an ideal investment," says Kurtzman of PixelOptics' new product, the result of 12 years of research.

Kurtzman, who is already wearing a pair of the glasses, is impressed that he can use the entire lens for either purpose. "There is a small liquid crystal embedded in the glass of the lens. If I need it, I turn it on and it's there." He reports that the glasses are the same weight as their conventional counterparts, and the company is initially rolling out 36 different frames, competitively priced, in a variety of shapes and colors. Kurtzman says emPower! frames will be available in the Philadelphia area within six months.

Source: Gary Kurtzman MD, Safeguard Scientifics
Writer: Sue Spolan

Adaptimmune brings tools in the fight against cancer, HIV/AIDS to Science Center

Flying Kite Media Tuesday, March 29, 2011

Imagine cancer treatment without debilitating chemotherapy and damaging radiation. Researchers in the field of fighting cancer and infectious diseases have recently come up with a way to remove, edit and replace patients' own cells to turn them into cancer and HIV super soldiers in the body. Adaptimmune LLC, one of University City Science Center's newest tenants, is the first company of its kind to develop a methodology for generating high affinity T cell receptors. Dr. Gwen Binder-Scholl, the Vice President of Operations at Adaptimmune, says that this powerful approach is a major departure from previous forms of cancer and infectious disease treatment, offering the advantage of much higher potency with far fewer side effects.

Traditional chemotherapy attacks any rapidly dividing cell in the body, knocking out cancerous tumors, but also killing cells that generate hair and mucous membranes. In this new treatment paradigm, T cells, which are the body's immune soldiers, are harvested from the patient, modified and placed in cell factories to grow, and then returned to the patient via vaccine. The whole process takes only three weeks from manufacture to release, according to Binder-Scholl, so that cancer and HIV can be treated fairly quickly.

"We are really the only company taking the next step towards commercialization of adoptive T cell therapy with high affinity TCRs," says Binder-Scholl, who has been working on T cell receptor research at the University of Pennsylvania's Abramson Family Cancer Research Institute for about three years at the June Laboratory under the guidance of professor Carl June, MD. Binder-Scholl explains that Adaptimmune, a subsidiary of a UK company, approached her to manage and carry forth U.S. clinical trials. While Adaptimmune already has a close relationship with Penn, its overseas leadership qualifies it for the SciCenter's Global Soft Landing Program.

This month, Adaptimmune is opening three new oncology indications: a trial for melanoma, which is very common, and trials for the less frequently occurring cancers synovial sarcoma and multiple myeloma. Depending on how the clinical trials go, Binder-Scholl expects to see data emerge within 12 months and hopes to get approval for the experimental treatment with the decade.

Source: Gwen Binder-Scholl, Adaptimmune LLC
Writer: Sue Spolan

Optofluidics' technology combines fluids, light to develop better diagnostic tools

Flying Kite Media Tuesday, March 22, 2011

It's one minuscule step for molecules, one giant leap for mankind. Nanotechnology startup Optofluidics, Inc. has established offices at the University City Science Center's Port Business Incubator. The company aims to develop optical devices that keep biomolecules in place in their physiological state, says Optofluidic's Chief Technology Officer and co-founder, Bernardo Cordovez. "The product will be an instrument that houses and reads the chips that we make."

As the company name implies, Optofluidics uses the combination of fluids and light to detect, identify and manipulate biomolecules and nanomaterials. The idea of adding fluids to scientific optical devices is not a new one. Back in the 18th century, rotating pools of mercury were used to create smooth mirrors in reflecting telescopes. According to Cornell University's Erikson Lab, where Optofluidics co-founder David Erikson initiated research concepts for Optofluidics, new biosensing technologies follow advances in the identification of biomarkers associated with specific diseases and injuries. Two examples are the neurodegenerative diseases Alzheimer's and Parkinson's, which have eluded early detection. The kind of non-invasive nanotechnology that Optofluidics is developing, which will diagnose and detect biomarkers at very low levels, could enable diagnosis even before symptoms appear.

The National Science Foundation recently gave Optofluidics nearly $150,000 in a Small Business Innovation Research award. "The market opportunity is tremendous because most single molecule instrumentation is made for DNA, while nano-instrumentation for handling and studying proteins is still a bit behind," says Cordovez, who adds that Optofluidics' family of technologies has very strong commercial appeal.
Making the move to the Science Center was the easy part. Cordovez cites the University of Pennsylvania's strong biosciences department which will provide "a terrific future employee candidate pool." Philadelphia is slated to become a world leader in nanotechnology research, says Cordovez, with a planned world class nanofabrication center at Penn, scheduled for completion in the next few years.

Source: Bernard Cordovez, Optofluidics, Inc.
Writer: Sue Spolan

Kensington's Perfect Prototype creates new realities

Flying Kite Media Tuesday, March 15, 2011

A three dimensional rendering of a human heart is beating atop a card you hold in your hand. It's not reality, it's Augmented Reality, the latest method of bringing two dimensional images into a 3D world. Augmented Reality images exist only on the screen of a computer or mobile device, but with the addition of a live camera feed, viewing the virtual sculptures feels astoundingly real.

Perfect Prototype describes itself as an interactives company, "telling stories with innovative technology to create engaging, educational experiences for people," says Matthew Browning, company president. Located in the Crane Arts building, Perfect Prototype flies under local radar but is creating a national splash with projects for educational and corporate clients, such as a museum exhibit that lets you hold a virtual brain in your hands, a locomotive simulator that provides the virtual experience of operating a train, and a presentation to a corporate audience that integrates 3D animations. And if you are in the mood for some new fashioned hand to hand combat, Browning says Perfect Prototype has come up with a device that allows people across the country to arm-wrestle.

Browning, who is working overtime along with ten independent professionals to meet customer need, says clients range from museums such as Chicago's Museum of Science and Industry, to corporations including Norfolk Southern and Hyundai, along with the NHL's Pittsburgh Penguins.

Perfect Prototype is at the forefront of a rapidly growing technology that has implications across many sectors. Browning says of the technology that is still in its infancy, "There is so much untapped potential in Augmented Reality. It's a joy to push the limits and create new and innovative uses." And, he adds, with increased computing power on mobile and stationary devices, Perfect Protoype continues to give people a new experience, and a new way of looking at the world around them.

Source: Matthew Browning, Perfect Prototype
Writer: Sue Spolan

An incredibly more edible egg, thanks to Penn Vet school

Flying Kite Media Tuesday, March 01, 2011

The egg comes first in the conversation about food safety. Both poultry and egg production are on the rise in the US. According to the USDA's most recent Census of Agriculture, sales have increased 55 percent in the last decade. But it's egg safety that's in the news. On the heels of a massive egg recall last summer, University of Pennsylvania researchers have developed a new test to detect the presence of Salmonella in eggs.

Shelley Rankin, an Associate Professor of Microbiology at Penn's School of Veterinary Medicine, says the kit, which detects Salmonella enteritidis, or SE, a strain of Salmonella specific to eggs, provides results in just 27 hours. Rankin explains that the Food and Drug Administration's new Federal Egg Safety Program, instituted in July of last year, was based in part on the Pennsylvania Egg Quality Assurance Program (PEQAP), which was developed by Rankin and colleagues. "I wanted Pennsylvania to be the first state to get a novel, non-culture based test approved by the FDA for our producers to use," says Rankin.

Previous FDA guidelines required some expensive and laborious methods, taking up to ten days to see results. "At that point my colleagues and I within the PEQAP decided we should look for a better method," according to Rankin, whose team was able to identify a gene that is present only in SE. Working in collaboration with California based company Life Technologies, which already sells kits for detection of more than 2500 strains of Salmonella, the new kit focuses a laser, literally, on potential SE contamination. Polymerase Chain Reaction technology amplifies a small segment of the gene which lights up and is detectable via laser. If the light goes on, says Rankin, then SE is present. The Applied Biosystems TaqMan Salmonella enteritidis Detection Kit is FDA approved and contains 96 single-use tests.

"I chose to work with an industry partner to make that test available nationwide to improve the public health of the nation," adds Rankin. Plans are underway, says Rankin, to further reduce testing time from 27 to 12 hours.

Source: Shelley Rankin, PhD, University of Pennsylvania School of Veterinary Medicine
Writer: Sue Spolan

FLYING BYTES: PHL to QUE, Drexel and Boeing, and Mutual Funds from Hedge Funds

Flying Kite Media Tuesday, February 15, 2011

Flying Bytes is innovation nuggets from around the region:

CALLING ALL FRANCOPHILE JETSETTERS
Get your beret and cafe au lait. This summer, US Airways starts direct flights from Philadelphia to Quebec City. The daily, year round service begins June 2 and offers three nonstop round trip flights. The quick trip to the Quebec capital is under 2 hours each way.

THE LONG AND $HORT OF IT
Turner Investments of Berwyn announced the launch this week of three alternative mutual funds that employ hedge fund strategies. The Medical Sciences Long/Short, the Market Neutral and the Titan Fund all rely on diversified long and short investments. Matt Glaser, who manages the Market Neutral, says the funds seek to deliver superior risk adjustment return for clients. "Post financial crisis investors are looking for ways to mitigate risk and lower volatility, so hedge funds, and mutual fund vehicles are here to stay."

EARLY TAKEOFF
Drexel University engineering students will be working on Boeing projects, thanks to a long term agreement signed this week between CDI-Aerospace and Boeing. Through the school's co-operative education program, students will be working on structural designs, software conversions and stress analysis for the CH-47 military helicopter, the V-22 Osprey vertical takeoff and landing aircraft and the Boeing 787 commercial transport aircraft.

STEAMPUNK ACTION
The Kensington Kinetic Sculpture Derby is back for its 5th year, and organizers have put out a call for entries. Last year, participants crafted a bicycle powered steam engine, a conveyance that catapulted paint filled balloons onto a canvas, pirate ships and dragons, all foot powered. If your passion lives at the intersection of biking and art, visit the Sculpture Derby's home page for guidelines and registration forms. The event takes place May 21, and submit your entry form by April 15 to get free T-shirts for your team.

Source: USAirways; Henry Pyatt, Kensington Kinetic Sculpture Derby; Matt Glaser, Turner Investments, CDI
Writer: Sue Spolan

A toast to patient compliance at upcoming Cocktail Convention

Flying Kite Media Tuesday, February 15, 2011

Why aren't you taking your drugs? The age old question is getting new treatment at an upcoming summit of health care professionals, pharmaceutical manufacturers, patients and advocates. On Feb. 24, Wool.labs Cocktail Convention offers a group with often diverging opinions the chance to duke it out over a beer.

The event, Patient Adherence Through the Lens of Social Media in the Healthcare Continuum, will be held at the National Constitution Center, and is co-sponsored by Wool.labs, SmartBrief, and MISI Company. Proceeds from ticket sales benefit the Prostate Cancer Foundation.

Michele Bennett is Wool.labs' COO and the moderator of the event, which, she says, is Wool.labs' way "of trying to promote more understanding in patient health care." She says the evening will begin with panelists from a wide range of perspectives, including the dynamic entrepreneur Paul Shiels, managing director of the Ansley Capital Group and a big proponent of using social media to both gather and spread information about health care. He cites Wool.labs' research into what people were saying online about Avandia well before the diabetes drug made headlines for increasing the risk of heart attack.

"It's startling, the level of sophistication that is discernible early on," says Shiels, who adds that Wool.labs' proprietary search engine is better than a focus group or survey based analysis, because it doesn't just go to medical pages, but instead searches every available website in the world to glean information on the relationship between patients and their medications. In fact, he says, quite a bit of Avandia chat was found on a forum for motorcycle enthusiasts.

Joining Shiels on the panel is Dan Zenka, Vice President of Communications for the Prostate Cancer Foundation. In what Zenka terms a "hugely ironic" turn of events, he himself was diagnosed with prostate cancer nearly a year ago, and immediately created the blog My New York Minute, a chronicle of his diagnosis and treatment. The site has racked up 24,000 reads since the first post in April 2010. Other guests include pharmacist Steve Basiago, oncologist Tim Showalter, and health care administrator Elizabeth Beer. Moderator Michele Bennett promises a thought provoking evening and maybe even some controversy.

Source: Michele Bennett, Wool.labs, Paul Shiels, Ansley Capital Group, Dan Zenka, Prostate Cancer Foundation
Writer: Sue Spolan

Belgian Firm Makes Soft Landing at Science Center, Hiring Sales Rep for Natural Enzyme Applications

Nicolas Tuesday, February 15, 2011

You may not be famliar with papain, bromelain and ficin, but they are all naturally occurring enzymes extracted from fruit trees and plants and used in a wide range of applications, including beer, cancer treatments and contact lens cleaner.

The newest tenant at the University City Science Center's Port Business Incubator (3624 Market St.) specializes in production and commercialization of those compounds and is hoping its entry to the U.S. market is just as naturally occurring. Belgium-based Enzbyel International announced last week it established its U.S. office through the Science Center's Global Soft Landing program,

According to Science Center spokesperson Jeanne Mell, the Global Soft Landing program, which helps global companies establish a presence in local life sciences and IT markets, has engaged eight companies--a number that figures to get larger as the Science Center expandsd its Global Soft Landing space at 3711 Market Street.

Nicolas Chatelain is Enzybel's lone employee at the Science Center and will focus on business development. He says Enzybel is actively seeking a second employee for its Philadelphia operations

"We would like to hire (someone) as a sales representative for the food ingredient and neutraceutical industries as soon as possible," he says. "We are looking for an American candidate that will have at least a Bachelor's degree in Food Science Chemistry or related discipline."

In addition to growing its food processing accounts and prospecting new markets, Enzybel is hoping to set up a joint venture with a distributor for its wastewater solution.

Source: Nicolas Chatelain, Enzybel; Jeanne Mell, University City Science Center
Writer: Joe Petrucci

Flying Bytes: Car Show opens, Beyond Abstract, growth at LLR, pulse of Pulsar

Flying Kite Media Tuesday, February 01, 2011

Flying Bytes is innovation nuggets from around Greater Philadelphia:

RIDING AROUND IN YOUR OLD BLUE JEANS:: there's been a huge increase in eco-friendly automotive offerings, all on display at the 2011 Philadelphia International Auto Show, but Ford goes one better, offering recycled denim seat cloth on some 2012 models, according to Violet Marley, who represents the car maker at the convention, which runs through Feb. 11. Also, this just in from The Automobile Dealers Association of Greater Philadelphia: 2011 show attendance jumped 28.4 percent from last year's opening weekend. That translates to 65,984 attendees in just two days, the third largest tally in the show's history.

DRIVEN TO ABSTRACTION: This is the last week you can catch Beyond Abstraction at the Center For Emerging Visual Artists at 1521 Locust Street, Philadelphia. Curated by Katrin Elia, the group show gathers the work of eight contemporary artists working in a range of media from canvas to video. While most shows begin with a subject in search of an artist, says Elia, Beyond Abstraction gathered artists first and came up with the umbrella concept later.

CAR POOL EQUITY: LLR Partners, a private equity mezzanine finance company, continues to grow, announcing four new hires this week. Jack Slye is the firm's new Vice President; Irene Lisyansky and Brian Berkin are LLR's newest Senior Associates, and Scott Williams takes the lead as Senior Analyst. LLR manages over $1.4 billion, providing interim and secondary financing to middle market companies in the 'financial, health care and business services, information technology, and education." Recently, LLR invested in Avenues: The World School, a private K-12 to open its flagship in Manhattan, with schools planned for major cities around the world.

WAKE UP AND SMELL THE EXPANSION: Pulsar Informatics, a research facility that specializes in the "assessment of cognitive performance and fatigue risk management," has outgrown its original space in the University Science Center Port Business Incubator and is moving to quarters that are triple the size on the Science Center's campus. Pulsar's fatigue assessment tools are now in use by the Department of Defense, The Federal Aviation Administration, and NASA, among others.

Source: Violet Marley, Ford; Katrin Elia, Beyond Abstraction; LLR Partners, Pulsar Informatics
Writer: Sue Spolan